Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02402218 · ClinicalTrials.gov registry record · NA
CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS
A NA study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- NA
- Development phase
- 144
- Enrollment target
NCT02402218: Completed NA study, sponsored by Johns Hopkins University.
NCT02402218 is a NA study that has completed, run by Johns Hopkins University. The registered enrollment target is 144 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02402218, a NA study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- NA
- Development phase
- 144 participants
- Enrollment target
Study Summary
This study is being done to compare three strategies to deliver HCV treatment with ledipasvir/sofosbuvir which is an approved therapy which is administered as one tablet by mouth daily for 12 weeks. The study population is persons living with HIV and hepatitis C virus (HCV) coinfection who also use drugs. Participants will be randomized into one of three treatment groups: 1. Usual care in the clinic. This treatment group will receive the standard of care for HCV treatment from their health care team. 2. Usual care plus peer-mentors. In addition to the usual care, this is an investigational strategy in which participants assigned to this group will be asked to interact with a peer-mentor who is someone who has been cured of their HCV infection. 3. Usual care plus incentives. In addition to the usual care, this is an investigational strategy in which participants assigned to this group will be given incentives after completing certain treatment goals during the course of the study. HCV treatment with ledipasvir/sofosbuvir is considered the standard of care for HCV and is recommended by experts in liver disease and infectious diseases.
Interventions
- OTHER Usual Care
- OTHER Usual care plus peer-mentors
- OTHER Usual care plus incentives
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2015-08 |
| Est. Completion | 2017-06-21 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02402218
The ClinicalTrials.gov registry entry for NCT02402218 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Usual Care is the first listed.
NCT02402218 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02402218 about?
NCT02402218 is a clinical study titled "CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS". This study is being done to compare three strategies to deliver HCV treatment with ledipasvir/sofosbuvir which is an approved therapy which is administered as one tablet by mouth daily for 12 weeks. The study population is persons living with HIV and hepatitis C virus (HCV) coinfection who also use ...
What is the current status of trial NCT02402218?
This trial is currently completed. It is a NA study. The enrollment target is 144 participants. The study started on 2015-08. Estimated completion is 2017-06-21.
What interventions are being tested in trial NCT02402218?
The interventions under investigation include: Usual Care (OTHER), Usual care plus peer-mentors (OTHER), Usual care plus incentives (OTHER).
Who is sponsoring clinical trial NCT02402218?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.